1280 related articles for article (PubMed ID: 14656927)
1. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
[TBL] [Abstract][Full Text] [Related]
2. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo.
Passier R; Zeng H; Frey N; Naya FJ; Nicol RL; McKinsey TA; Overbeek P; Richardson JA; Grant SR; Olson EN
J Clin Invest; 2000 May; 105(10):1395-406. PubMed ID: 10811847
[TBL] [Abstract][Full Text] [Related]
3. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.
Sanna B; Bueno OF; Dai YS; Wilkins BJ; Molkentin JD
Mol Cell Biol; 2005 Feb; 25(3):865-78. PubMed ID: 15657416
[TBL] [Abstract][Full Text] [Related]
4. The Ca(v)3.2 T-type Ca(2+) channel is required for pressure overload-induced cardiac hypertrophy in mice.
Chiang CS; Huang CH; Chieng H; Chang YT; Chang D; Chen JJ; Chen YC; Chen YH; Shin HS; Campbell KP; Chen CC
Circ Res; 2009 Feb; 104(4):522-30. PubMed ID: 19122177
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.
Fiedler B; Lohmann SM; Smolenski A; Linnemuller S; Pieske B; Schroder F; Molkentin JD; Drexler H; Wollert KC
Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11363-8. PubMed ID: 12177418
[TBL] [Abstract][Full Text] [Related]
7. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1.
Musarò A; McCullagh KJ; Naya FJ; Olson EN; Rosenthal N
Nature; 1999 Aug; 400(6744):581-5. PubMed ID: 10448862
[TBL] [Abstract][Full Text] [Related]
8. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy.
Wilkins BJ; Molkentin JD
Biochem Biophys Res Commun; 2004 Oct; 322(4):1178-91. PubMed ID: 15336966
[TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling.
Braz JC; Bueno OF; Liang Q; Wilkins BJ; Dai YS; Parsons S; Braunwart J; Glascock BJ; Klevitsky R; Kimball TF; Hewett TE; Molkentin JD
J Clin Invest; 2003 May; 111(10):1475-86. PubMed ID: 12750397
[TBL] [Abstract][Full Text] [Related]
10. Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure.
Diedrichs H; Chi M; Boelck B; Mehlhorn U; Schwinger RH
Eur J Heart Fail; 2004 Jan; 6(1):3-9. PubMed ID: 15012912
[TBL] [Abstract][Full Text] [Related]
11. Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis.
Mohamed BA; Barakat AZ; Zimmermann WH; Bittner RE; Mühlfeld C; Hünlich M; Engel W; Maier LS; Adham IM
J Mol Cell Cardiol; 2012 Oct; 53(4):459-68. PubMed ID: 22884543
[TBL] [Abstract][Full Text] [Related]
12. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
Nakamura TY; Iwata Y; Arai Y; Komamura K; Wakabayashi S
Circ Res; 2008 Oct; 103(8):891-9. PubMed ID: 18776042
[TBL] [Abstract][Full Text] [Related]
13. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
[TBL] [Abstract][Full Text] [Related]
14. Syndecan-4 is essential for development of concentric myocardial hypertrophy via stretch-induced activation of the calcineurin-NFAT pathway.
Finsen AV; Lunde IG; Sjaastad I; Østli EK; Lyngra M; Jarstadmarken HO; Hasic A; Nygård S; Wilcox-Adelman SA; Goetinck PF; Lyberg T; Skrbic B; Florholmen G; Tønnessen T; Louch WE; Djurovic S; Carlson CR; Christensen G
PLoS One; 2011; 6(12):e28302. PubMed ID: 22164265
[TBL] [Abstract][Full Text] [Related]
15. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.
Takimoto E; Champion HC; Li M; Belardi D; Ren S; Rodriguez ER; Bedja D; Gabrielson KL; Wang Y; Kass DA
Nat Med; 2005 Feb; 11(2):214-22. PubMed ID: 15665834
[TBL] [Abstract][Full Text] [Related]
16. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs.
Molkentin JD
Cardiovasc Res; 2004 Aug; 63(3):467-75. PubMed ID: 15276472
[TBL] [Abstract][Full Text] [Related]
17. TAK1 Regulates Myocardial Response to Pathological Stress via NFAT, NFκB, and Bnip3 Pathways.
Li L; Chen Y; Li J; Yin H; Guo X; Doan J; Molkentin JD; Liu Q
Sci Rep; 2015 Nov; 5():16626. PubMed ID: 26564789
[TBL] [Abstract][Full Text] [Related]
18. Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice.
Oliveira RS; Ferreira JC; Gomes ER; Paixão NA; Rolim NP; Medeiros A; Guatimosim S; Brum PC
J Physiol; 2009 Aug; 587(Pt 15):3899-910. PubMed ID: 19505981
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin Abeta gene targeting predisposes the myocardium to acute ischemia-induced apoptosis and dysfunction.
Bueno OF; Lips DJ; Kaiser RA; Wilkins BJ; Dai YS; Glascock BJ; Klevitsky R; Hewett TE; Kimball TR; Aronow BJ; Doevendans PA; Molkentin JD
Circ Res; 2004 Jan; 94(1):91-9. PubMed ID: 14615291
[TBL] [Abstract][Full Text] [Related]
20. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling.
Liang Q; Bueno OF; Wilkins BJ; Kuan CY; Xia Y; Molkentin JD
EMBO J; 2003 Oct; 22(19):5079-89. PubMed ID: 14517246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
